Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Marquette University
The study design is to treat individuals suffering from mild to moderate exacerbations of asthma with nebulized salbutamol (2.5mg). Subjects will receive nebulization using either an electric nebulizer compressor or a human-powered nebulizer compressor. Improvement in peak expiratory flow will be the primary endpoint. Blood oxygenation levels as measured by pulse oximetry will be a secondary endpoint of the trial.
Age
6–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Suffering from Mild or Moderate Asthma symptoms
Increased respiratory rate, but not over 30 breaths per minute
Reduced peak expiratory flow rate, but not less than 60% of normal
Oxygen saturation levels reduced but greater than 90%
You may not be if
Any other respiratory condition that would interfere with nebulizer treatment
If any other medication is being taken at the time
Pregnant women or women who may think they might be pregnant
